Phase Forward Names Steve Powell Vice President of Worldwide Sales; Co

    Pharmaceutical Writers/Business Editors/Technology
    Writers/Healthcare Editors

    WALTHAM, Mass.--(BUSINESS WIRE)--March 7, 2005--Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Steve Powell, vice president and general manager, international, will now assume responsibility for the company's worldwide sales function in addition to his current role running international sales and operations.
    Steve Powell has been managing Phase Forward's international sales and operations since January 1999. During his tenure, Powell has grown the international business to represent 43% of the company's overall revenues in 2004 and has helped drive the adoption of the InForm(TM) electronic data capture (EDC) solution in over 650 trials, at over 20,000 sites, in 90 countries around the world. In addition, Powell built a world-class customer support organization, offering assistance in 18 languages, 24 hours a day, seven days a week. Under his direction, Phase Forward's international presence has grown to include offices in the United Kingdom, Australia, France, and Japan.
    "Steve has made a major impact on our international business by building an excellent team of people and driving significant revenue growth," said Bob Weiler, president and chief executive officer, Phase Forward. "He has been vital to the success of Phase Forward and its recent move from private to public company." Phase Forward was recently named to Inc. 500's list of fastest growing companies in the United States.
    Jason Reynolds will assume the role of vice president of North American sales. Reynolds has been with the Phase Forward North American sales organization since 1998 and currently holds the position of director, North American sales. Reynolds has played a critical role in establishing some of Phase Forward's most important customer relationships and building the North American sales organization. John Hamilton, current vice president of North American sales, will be leaving Phase Forward to pursue other interests. Hamilton will remain with Phase Forward through the end of March 2005 to assist in the transition process.
    Weiler went on to say, "I'm extremely pleased to be able to fill these positions from within our company. Jason and Steve's new roles speak to the wealth of talent within the organization and our ability to develop our employees."

    About Phase Forward

    Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company helps pharmaceutical, biotechnology, and medical device companies bring needed drugs and therapies to market faster and more safely. Phase Forward offers proven solutions in electronic data capture (EDC), clinical data management (CDM), and adverse event reporting (AER). Phase Forward products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 200 organizations worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Cedars-Sinai, Eli Lilly and Company, GlaxoSmithKline, Guidant, Procter & Gamble, Quintiles, Sanofi-Aventis, and Schering-Plough Research Institute. Additional information about Phase Forward is available at www.phaseforward.com.

    Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, Phase Forward's expectations concerning its future sales, its personnel, and/or its business outlook. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward to drive future sales and revenue growth, retain skilled personnel, and manage its global operations effectively. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, it's most recent Annual Report on Forms 10-Q.

--30--NC/bo*

CONTACT: Phase Forward Public Relations Pam Sullivan, 781-902-4502 pam.sullivan@phaseforward.com or QORVIS Communications Investor Relations Karen Vahouny, 703-744-7809 kvahouny@qorvis.com

KEYWORD: MASSACHUSETTS INTERNATIONAL ASIA PACIFIC EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Phase Forward

Copyright Business Wire 2005